LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Aandelen Lijst・Novavax Inc

Novavax Inc

Gesloten

SectorGezondheidszorg

8.45 -5.69

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.43

Max

8.96

Belangrijke statistieken
By Trading Economics
Inkomsten	220M 18M
Verkoop	77M 147M
K/W Sectorgemiddelde	3.767 57.05
EPS	0.11
Winstmarge	11.912
Werknemers	749
EBITDA	220M 29M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+41.56% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	63M 1.6B
Vorige openingsprijs	14.14
Vorige sluitingsprijs	8.45

Nieuwssentiment

By Acuity

51%

49%

273 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

5.692 / 6.039 Steun & Weerstand

Novavax Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 apr 2025, 17:06 UTC

Belangrijke Marktbewegers

Novavax Falls But Then Recovers After WSJ Report on Vaccine's FDA Status

31 mrt 2025, 14:19 UTC

Belangrijke Marktbewegers

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

19 mei 2025, 14:30 UTC

Top Nieuws

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker. -- Barrons.com

19 mei 2025, 13:27 UTC

Top Nieuws

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker. -- Barrons.com

8 mei 2025, 17:55 UTC

Winsten

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

8 mei 2025, 15:12 UTC

Winsten

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

28 apr 2025, 17:04 UTC

Winsten

Novavax Stock Is Up Again. There Are Still Big Questions About the Fate of Its Covid Shot. -- Barrons.com

Peer Vergelijking

Prijswijziging

Novavax Inc Prognose

Koersdoel

By TipRanks

41.56% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 12.67 USD 41.56%

Hoogste 19 USD

Laagste 7 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Novavax Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Novavax Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.692 / 6.039Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

273 / 349 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.